Overview

• The settlement allocates $6.5 billion from the Sackler family and $900 million from Purdue Pharma, payable over 15 years with most funds frontloaded in the first three years.
• It ends the Sackler family’s ownership of Purdue Pharma and bars both the family and the company from manufacturing or selling opioids in the United States.
• Funds are earmarked for addiction treatment, prevention and recovery programs nationwide, with California, New York and New Jersey among the top recipients.
• Creditors including local governments and individual claimants may opt out to preserve their right to pursue separate lawsuits against Sackler family members.
• U.S. Bankruptcy Judge Sean Lane will hear confirmation arguments on November 10, 2025, after which affected parties will vote on the restructuring plan.